Skip to main content

Table 4 Observed Incidence of Febrile Neutropenia

From: Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

  RGB-02 Reference Difference(RGB-02 - Reference)
Cycle 1, PP population
 n 117 113  
 n (%) with febrile neutropenia 5 (4.3) 4 (3.5)  
 Proportion (95% CI) with febrile neutropenia 0.043 (0.014, 0.097) 0.035(0.010, 0.088) 0.007(−0.123, 0.137)
Cycle 2, PP population
 n 111 103  
 n (%) with febrile neutropenia 0 0